nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—Methotrexate—esophageal cancer	0.324	0.436	CbGbCtD
Alprostadil—ABCC5—Cisplatin—esophageal cancer	0.319	0.43	CbGbCtD
Alprostadil—ABCC4—Methotrexate—esophageal cancer	0.0994	0.134	CbGbCtD
Alprostadil—PTGER2—trachea—esophageal cancer	0.00478	0.0838	CbGeAlD
Alprostadil—SLCO2A1—neck—esophageal cancer	0.00407	0.0713	CbGeAlD
Alprostadil—PTGER2—lung—esophageal cancer	0.00343	0.0602	CbGeAlD
Alprostadil—PTGIR—epithelium—esophageal cancer	0.00317	0.0555	CbGeAlD
Alprostadil—PTGIR—smooth muscle tissue—esophageal cancer	0.00305	0.0535	CbGeAlD
Alprostadil—Fibrosis—Cisplatin—esophageal cancer	0.00291	0.0417	CcSEcCtD
Alprostadil—SLCO2A1—epithelium—esophageal cancer	0.00277	0.0485	CbGeAlD
Alprostadil—SLCO3A1—bronchus—esophageal cancer	0.00275	0.0482	CbGeAlD
Alprostadil—SLCO2A1—bronchus—esophageal cancer	0.00273	0.0478	CbGeAlD
Alprostadil—ABCC5—bronchus—esophageal cancer	0.00249	0.0437	CbGeAlD
Alprostadil—SLCO2A1—trachea—esophageal cancer	0.00245	0.0429	CbGeAlD
Alprostadil—PTGIR—digestive system—esophageal cancer	0.00241	0.0422	CbGeAlD
Alprostadil—PTGER2—lymph node—esophageal cancer	0.00235	0.0412	CbGeAlD
Alprostadil—Fibrosis—Capecitabine—esophageal cancer	0.00214	0.0308	CcSEcCtD
Alprostadil—PTGIR—lung—esophageal cancer	0.00201	0.0353	CbGeAlD
Alprostadil—SLCO3A1—lung—esophageal cancer	0.00178	0.0311	CbGeAlD
Alprostadil—SLCO2A1—lung—esophageal cancer	0.00176	0.0308	CbGeAlD
Alprostadil—ABCC4—bronchus—esophageal cancer	0.00173	0.0303	CbGeAlD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS1—esophageal cancer	0.00171	0.492	CrCbGaD
Alprostadil—ABCC5—lung—esophageal cancer	0.00161	0.0282	CbGeAlD
Alprostadil—Fibrosis—Methotrexate—esophageal cancer	0.0016	0.0229	CcSEcCtD
Alprostadil—Nodule—Methotrexate—esophageal cancer	0.00155	0.0223	CcSEcCtD
Alprostadil—SLCO2B1—digestive system—esophageal cancer	0.00151	0.0264	CbGeAlD
Alprostadil—Tooth abscess—Capecitabine—esophageal cancer	0.00147	0.021	CcSEcCtD
Alprostadil—PTGIR—lymph node—esophageal cancer	0.00138	0.0241	CbGeAlD
Alprostadil—Diabetic—Methotrexate—esophageal cancer	0.00137	0.0196	CcSEcCtD
Alprostadil—Serum creatinine increased—Cisplatin—esophageal cancer	0.00135	0.0194	CcSEcCtD
Alprostadil—ABCC4—digestive system—esophageal cancer	0.00133	0.0234	CbGeAlD
Alprostadil—Anuria—Methotrexate—esophageal cancer	0.00131	0.0187	CcSEcCtD
Alprostadil—SLCO2B1—lung—esophageal cancer	0.00126	0.0221	CbGeAlD
Alprostadil—Pneumothorax—Capecitabine—esophageal cancer	0.00123	0.0177	CcSEcCtD
Alprostadil—SLCO3A1—lymph node—esophageal cancer	0.00121	0.0213	CbGeAlD
Alprostadil—SLCO2A1—lymph node—esophageal cancer	0.0012	0.0211	CbGeAlD
Alprostadil—ABCC4—lung—esophageal cancer	0.00111	0.0195	CbGeAlD
Alprostadil—ABCC5—lymph node—esophageal cancer	0.0011	0.0193	CbGeAlD
Alprostadil—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.00107	0.0153	CcSEcCtD
Alprostadil—Infection—Carboplatin—esophageal cancer	0.001	0.0144	CcSEcCtD
Alprostadil—Serum creatinine increased—Capecitabine—esophageal cancer	0.000996	0.0143	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—esophageal cancer	0.000979	0.281	CrCbGaD
Alprostadil—Haematoma—Capecitabine—esophageal cancer	0.000975	0.014	CcSEcCtD
Alprostadil—Respiratory distress—Capecitabine—esophageal cancer	0.000965	0.0138	CcSEcCtD
Alprostadil—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.000935	0.0134	CcSEcCtD
Alprostadil—Blood triglycerides increased—Capecitabine—esophageal cancer	0.000935	0.0134	CcSEcCtD
Alprostadil—Pain—Carboplatin—esophageal cancer	0.000865	0.0124	CcSEcCtD
Alprostadil—SLCO2B1—lymph node—esophageal cancer	0.000861	0.0151	CbGeAlD
Alprostadil—Hyperkalaemia—Cisplatin—esophageal cancer	0.000817	0.0117	CcSEcCtD
Alprostadil—Wheezing—Cisplatin—esophageal cancer	0.000807	0.0116	CcSEcCtD
Alprostadil—Ventricular fibrillation—Capecitabine—esophageal cancer	0.0008	0.0115	CcSEcCtD
Alprostadil—Body temperature increased—Carboplatin—esophageal cancer	0.000799	0.0115	CcSEcCtD
Alprostadil—Fungal infection—Capecitabine—esophageal cancer	0.000794	0.0114	CcSEcCtD
Alprostadil—Dinoprostone—CYP19A1—esophageal cancer	0.000788	0.226	CrCbGaD
Alprostadil—Multiple fractures—Methotrexate—esophageal cancer	0.000785	0.0113	CcSEcCtD
Alprostadil—Fracture—Methotrexate—esophageal cancer	0.000785	0.0113	CcSEcCtD
Alprostadil—ABCC4—lymph node—esophageal cancer	0.000762	0.0134	CbGeAlD
Alprostadil—Injection site pain—Capecitabine—esophageal cancer	0.00075	0.0108	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.000683	0.0098	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000674	0.00966	CcSEcCtD
Alprostadil—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000665	0.00954	CcSEcCtD
Alprostadil—Nasal congestion—Cisplatin—esophageal cancer	0.000662	0.0095	CcSEcCtD
Alprostadil—Burning sensation—Methotrexate—esophageal cancer	0.000657	0.00942	CcSEcCtD
Alprostadil—Injection site reaction—Capecitabine—esophageal cancer	0.000609	0.00874	CcSEcCtD
Alprostadil—Influenza like illness—Capecitabine—esophageal cancer	0.000595	0.00854	CcSEcCtD
Alprostadil—Fungal infection—Methotrexate—esophageal cancer	0.000591	0.00847	CcSEcCtD
Alprostadil—Blood creatinine increased—Cisplatin—esophageal cancer	0.000565	0.00811	CcSEcCtD
Alprostadil—Ecchymosis—Capecitabine—esophageal cancer	0.000554	0.00795	CcSEcCtD
Alprostadil—Hypokalaemia—Cisplatin—esophageal cancer	0.000549	0.00788	CcSEcCtD
Alprostadil—Apnoea—Methotrexate—esophageal cancer	0.000538	0.00772	CcSEcCtD
Alprostadil—Abnormal vision—Capecitabine—esophageal cancer	0.000534	0.00767	CcSEcCtD
Alprostadil—Sepsis—Capecitabine—esophageal cancer	0.000532	0.00763	CcSEcCtD
Alprostadil—Diabetes mellitus—Capecitabine—esophageal cancer	0.000511	0.00733	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.000508	0.00729	CcSEcCtD
Alprostadil—Sweating increased—Cisplatin—esophageal cancer	0.000508	0.00729	CcSEcCtD
Alprostadil—Swelling—Capecitabine—esophageal cancer	0.000504	0.00723	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000502	0.00719	CcSEcCtD
Alprostadil—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000458	0.00657	CcSEcCtD
Alprostadil—Renal failure—Cisplatin—esophageal cancer	0.000457	0.00656	CcSEcCtD
Alprostadil—Myocardial infarction—Cisplatin—esophageal cancer	0.000456	0.00654	CcSEcCtD
Alprostadil—Lethargy—Capecitabine—esophageal cancer	0.000454	0.00651	CcSEcCtD
Alprostadil—Pain in extremity—Capecitabine—esophageal cancer	0.000445	0.00638	CcSEcCtD
Alprostadil—Bradycardia—Cisplatin—esophageal cancer	0.000425	0.0061	CcSEcCtD
Alprostadil—Cardiac arrest—Capecitabine—esophageal cancer	0.000423	0.00607	CcSEcCtD
Alprostadil—Blood creatinine increased—Capecitabine—esophageal cancer	0.000417	0.00598	CcSEcCtD
Alprostadil—Ecchymosis—Methotrexate—esophageal cancer	0.000412	0.00592	CcSEcCtD
Alprostadil—Urethral disorder—Cisplatin—esophageal cancer	0.000409	0.00587	CcSEcCtD
Alprostadil—Hypokalaemia—Capecitabine—esophageal cancer	0.000405	0.00581	CcSEcCtD
Alprostadil—Visual impairment—Cisplatin—esophageal cancer	0.000402	0.00577	CcSEcCtD
Alprostadil—Sepsis—Methotrexate—esophageal cancer	0.000396	0.00568	CcSEcCtD
Alprostadil—Flushing—Cisplatin—esophageal cancer	0.000387	0.00556	CcSEcCtD
Alprostadil—Influenza—Capecitabine—esophageal cancer	0.000384	0.00551	CcSEcCtD
Alprostadil—Diabetes mellitus—Methotrexate—esophageal cancer	0.000381	0.00546	CcSEcCtD
Alprostadil—Sweating increased—Capecitabine—esophageal cancer	0.000374	0.00537	CcSEcCtD
Alprostadil—Bronchitis—Capecitabine—esophageal cancer	0.00037	0.0053	CcSEcCtD
Alprostadil—Erythema—Cisplatin—esophageal cancer	0.000363	0.00521	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000357	0.00512	CcSEcCtD
Alprostadil—Muscle spasms—Cisplatin—esophageal cancer	0.000349	0.00501	CcSEcCtD
Alprostadil—Hyperglycaemia—Capecitabine—esophageal cancer	0.000347	0.00497	CcSEcCtD
Alprostadil—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000338	0.00485	CcSEcCtD
Alprostadil—Lethargy—Methotrexate—esophageal cancer	0.000338	0.00485	CcSEcCtD
Alprostadil—Renal failure—Capecitabine—esophageal cancer	0.000337	0.00483	CcSEcCtD
Alprostadil—Myocardial infarction—Capecitabine—esophageal cancer	0.000336	0.00482	CcSEcCtD
Alprostadil—Anaemia—Cisplatin—esophageal cancer	0.000336	0.00482	CcSEcCtD
Alprostadil—Urinary tract infection—Capecitabine—esophageal cancer	0.000333	0.00478	CcSEcCtD
Alprostadil—Haematuria—Capecitabine—esophageal cancer	0.000327	0.00469	CcSEcCtD
Alprostadil—Convulsion—Cisplatin—esophageal cancer	0.000315	0.00452	CcSEcCtD
Alprostadil—Bradycardia—Capecitabine—esophageal cancer	0.000313	0.00449	CcSEcCtD
Alprostadil—Haemoglobin—Capecitabine—esophageal cancer	0.000309	0.00444	CcSEcCtD
Alprostadil—Rhinitis—Capecitabine—esophageal cancer	0.000308	0.00442	CcSEcCtD
Alprostadil—Haemorrhage—Capecitabine—esophageal cancer	0.000308	0.00441	CcSEcCtD
Alprostadil—Hypoaesthesia—Capecitabine—esophageal cancer	0.000306	0.00439	CcSEcCtD
Alprostadil—Discomfort—Cisplatin—esophageal cancer	0.000306	0.00438	CcSEcCtD
Alprostadil—Pharyngitis—Capecitabine—esophageal cancer	0.000305	0.00438	CcSEcCtD
Alprostadil—Urethral disorder—Capecitabine—esophageal cancer	0.000302	0.00433	CcSEcCtD
Alprostadil—Oedema—Cisplatin—esophageal cancer	0.000297	0.00425	CcSEcCtD
Alprostadil—Visual impairment—Capecitabine—esophageal cancer	0.000297	0.00425	CcSEcCtD
Alprostadil—Infection—Cisplatin—esophageal cancer	0.000295	0.00423	CcSEcCtD
Alprostadil—Thrombocytopenia—Cisplatin—esophageal cancer	0.00029	0.00416	CcSEcCtD
Alprostadil—Tachycardia—Cisplatin—esophageal cancer	0.000289	0.00415	CcSEcCtD
Alprostadil—Skin disorder—Cisplatin—esophageal cancer	0.000288	0.00413	CcSEcCtD
Alprostadil—Hyperhidrosis—Cisplatin—esophageal cancer	0.000287	0.00411	CcSEcCtD
Alprostadil—Flushing—Capecitabine—esophageal cancer	0.000286	0.0041	CcSEcCtD
Alprostadil—Hypotension—Cisplatin—esophageal cancer	0.000277	0.00397	CcSEcCtD
Alprostadil—Erythema—Capecitabine—esophageal cancer	0.000268	0.00384	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000266	0.00382	CcSEcCtD
Alprostadil—Back pain—Capecitabine—esophageal cancer	0.000259	0.00372	CcSEcCtD
Alprostadil—Muscle spasms—Capecitabine—esophageal cancer	0.000258	0.00369	CcSEcCtD
Alprostadil—Pain—Cisplatin—esophageal cancer	0.000254	0.00364	CcSEcCtD
Alprostadil—Renal failure—Methotrexate—esophageal cancer	0.000251	0.0036	CcSEcCtD
Alprostadil—Anaemia—Capecitabine—esophageal cancer	0.000248	0.00355	CcSEcCtD
Alprostadil—Feeling abnormal—Cisplatin—esophageal cancer	0.000244	0.00351	CcSEcCtD
Alprostadil—Haematuria—Methotrexate—esophageal cancer	0.000243	0.00349	CcSEcCtD
Alprostadil—Syncope—Capecitabine—esophageal cancer	0.00024	0.00345	CcSEcCtD
Alprostadil—Loss of consciousness—Capecitabine—esophageal cancer	0.000235	0.00338	CcSEcCtD
Alprostadil—Body temperature increased—Cisplatin—esophageal cancer	0.000234	0.00336	CcSEcCtD
Alprostadil—Cough—Capecitabine—esophageal cancer	0.000234	0.00335	CcSEcCtD
Alprostadil—Hypertension—Capecitabine—esophageal cancer	0.000231	0.00332	CcSEcCtD
Alprostadil—Haemoglobin—Methotrexate—esophageal cancer	0.00023	0.0033	CcSEcCtD
Alprostadil—Haemorrhage—Methotrexate—esophageal cancer	0.000229	0.00329	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—esophageal cancer	0.000227	0.00326	CcSEcCtD
Alprostadil—Discomfort—Capecitabine—esophageal cancer	0.000225	0.00323	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—esophageal cancer	0.000225	0.00322	CcSEcCtD
Alprostadil—Dry mouth—Capecitabine—esophageal cancer	0.000223	0.0032	CcSEcCtD
Alprostadil—Visual impairment—Methotrexate—esophageal cancer	0.000221	0.00317	CcSEcCtD
Alprostadil—Oedema—Capecitabine—esophageal cancer	0.000219	0.00314	CcSEcCtD
Alprostadil—Infection—Capecitabine—esophageal cancer	0.000217	0.00312	CcSEcCtD
Alprostadil—Shock—Capecitabine—esophageal cancer	0.000215	0.00308	CcSEcCtD
Alprostadil—Thrombocytopenia—Capecitabine—esophageal cancer	0.000214	0.00307	CcSEcCtD
Alprostadil—Tachycardia—Capecitabine—esophageal cancer	0.000213	0.00306	CcSEcCtD
Alprostadil—Asthenia—Cisplatin—esophageal cancer	0.000213	0.00305	CcSEcCtD
Alprostadil—Skin disorder—Capecitabine—esophageal cancer	0.000212	0.00305	CcSEcCtD
Alprostadil—Hyperhidrosis—Capecitabine—esophageal cancer	0.000211	0.00303	CcSEcCtD
Alprostadil—Hypotension—Capecitabine—esophageal cancer	0.000204	0.00293	CcSEcCtD
Alprostadil—Diarrhoea—Cisplatin—esophageal cancer	0.000203	0.00291	CcSEcCtD
Alprostadil—Erythema—Methotrexate—esophageal cancer	0.000199	0.00286	CcSEcCtD
Alprostadil—Back pain—Methotrexate—esophageal cancer	0.000193	0.00277	CcSEcCtD
Alprostadil—Dyspepsia—Capecitabine—esophageal cancer	0.000192	0.00276	CcSEcCtD
Alprostadil—Rash—Cisplatin—esophageal cancer	0.000187	0.00268	CcSEcCtD
Alprostadil—Pain—Capecitabine—esophageal cancer	0.000187	0.00268	CcSEcCtD
Alprostadil—Dermatitis—Cisplatin—esophageal cancer	0.000187	0.00268	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—esophageal cancer	0.000184	0.00264	CcSEcCtD
Alprostadil—Feeling abnormal—Capecitabine—esophageal cancer	0.00018	0.00258	CcSEcCtD
Alprostadil—Nausea—Cisplatin—esophageal cancer	0.000176	0.00253	CcSEcCtD
Alprostadil—Cough—Methotrexate—esophageal cancer	0.000174	0.0025	CcSEcCtD
Alprostadil—Abdominal pain—Capecitabine—esophageal cancer	0.000173	0.00248	CcSEcCtD
Alprostadil—Body temperature increased—Capecitabine—esophageal cancer	0.000173	0.00248	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—esophageal cancer	0.000173	0.00248	CcSEcCtD
Alprostadil—Discomfort—Methotrexate—esophageal cancer	0.000168	0.00241	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000162	0.00127	CbGpPWpGaD
Alprostadil—Infection—Methotrexate—esophageal cancer	0.000162	0.00232	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—esophageal cancer	0.000159	0.00229	CcSEcCtD
Alprostadil—ABCC5—Metabolism—SLC52A3—esophageal cancer	0.000159	0.00125	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—BLVRB—esophageal cancer	0.000159	0.00125	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKAP13—esophageal cancer	0.000158	0.00124	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000158	0.00124	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—GHRL—esophageal cancer	0.000158	0.00124	CbGpPWpGaD
Alprostadil—Skin disorder—Methotrexate—esophageal cancer	0.000158	0.00227	CcSEcCtD
Alprostadil—Hyperhidrosis—Methotrexate—esophageal cancer	0.000157	0.00226	CcSEcCtD
Alprostadil—Asthenia—Capecitabine—esophageal cancer	0.000157	0.00225	CcSEcCtD
Alprostadil—Pruritus—Capecitabine—esophageal cancer	0.000155	0.00222	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000153	0.0012	CbGpPWpGaD
Alprostadil—Hypotension—Methotrexate—esophageal cancer	0.000152	0.00218	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—ANXA1—esophageal cancer	0.000152	0.00119	CbGpPWpGaD
Alprostadil—Diarrhoea—Capecitabine—esophageal cancer	0.00015	0.00215	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—KMT2D—esophageal cancer	0.000148	0.00116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KMT2D—esophageal cancer	0.000148	0.00116	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—SST—esophageal cancer	0.000147	0.00115	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PDE4D—esophageal cancer	0.000145	0.00113	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000145	0.00113	CbGpPWpGaD
Alprostadil—Dizziness—Capecitabine—esophageal cancer	0.000145	0.00207	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—AKAP13—esophageal cancer	0.000144	0.00113	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKAP13—esophageal cancer	0.000144	0.00113	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—GHRL—esophageal cancer	0.000144	0.00113	CbGpPWpGaD
Alprostadil—Dyspepsia—Methotrexate—esophageal cancer	0.000143	0.00205	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—PFN1—esophageal cancer	0.000143	0.00112	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FKBP1A—esophageal cancer	0.000141	0.0011	CbGpPWpGaD
Alprostadil—Pain—Methotrexate—esophageal cancer	0.000139	0.002	CcSEcCtD
Alprostadil—Rash—Capecitabine—esophageal cancer	0.000138	0.00198	CcSEcCtD
Alprostadil—Dermatitis—Capecitabine—esophageal cancer	0.000138	0.00198	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—CFL1—esophageal cancer	0.000138	0.00108	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GNG7—esophageal cancer	0.000138	0.00108	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GNG7—esophageal cancer	0.000138	0.00108	CbGpPWpGaD
Alprostadil—ABCC5—Disease—DOCK2—esophageal cancer	0.000138	0.00108	CbGpPWpGaD
Alprostadil—ABCC5—Disease—WIF1—esophageal cancer	0.000138	0.00108	CbGpPWpGaD
Alprostadil—Headache—Capecitabine—esophageal cancer	0.000137	0.00196	CcSEcCtD
Alprostadil—ABCC5—Metabolism—SLC10A2—esophageal cancer	0.000135	0.00106	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CA1—esophageal cancer	0.000135	0.00106	CbGpPWpGaD
Alprostadil—Feeling abnormal—Methotrexate—esophageal cancer	0.000134	0.00192	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—ADCYAP1—esophageal cancer	0.000132	0.00103	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000132	0.00103	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ABL1—esophageal cancer	0.000131	0.00103	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PDE4D—esophageal cancer	0.000131	0.00103	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PDE4D—esophageal cancer	0.000131	0.00103	CbGpPWpGaD
Alprostadil—Nausea—Capecitabine—esophageal cancer	0.00013	0.00186	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—GNG7—esophageal cancer	0.00013	0.00102	CbGpPWpGaD
Alprostadil—Body temperature increased—Methotrexate—esophageal cancer	0.000129	0.00185	CcSEcCtD
Alprostadil—Abdominal pain—Methotrexate—esophageal cancer	0.000129	0.00185	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—ELMO1—esophageal cancer	0.000129	0.00101	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CSNK1A1—esophageal cancer	0.000127	0.000994	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKAP13—esophageal cancer	0.000126	0.000984	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GNG7—esophageal cancer	0.000125	0.000979	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GNG7—esophageal cancer	0.000125	0.000979	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CA2—esophageal cancer	0.000124	0.00097	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000124	0.00097	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL2—esophageal cancer	0.000121	0.00095	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000121	0.00095	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000121	0.000945	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—WWOX—esophageal cancer	0.00012	0.000944	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—WWOX—esophageal cancer	0.00012	0.000944	CbGpPWpGaD
Alprostadil—Asthenia—Methotrexate—esophageal cancer	0.000117	0.00167	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000116	0.000908	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ADH7—esophageal cancer	0.000115	0.000902	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PLCE1—esophageal cancer	0.000115	0.000902	CbGpPWpGaD
Alprostadil—Pruritus—Methotrexate—esophageal cancer	0.000115	0.00165	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—PDE4D—esophageal cancer	0.000115	0.0009	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FKBP1A—esophageal cancer	0.000115	0.000897	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FKBP1A—esophageal cancer	0.000115	0.000897	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000114	0.000896	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000113	0.000883	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—ANXA1—esophageal cancer	0.000113	0.000883	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000112	0.00088	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—WIF1—esophageal cancer	0.000112	0.000877	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—WIF1—esophageal cancer	0.000112	0.000877	CbGpPWpGaD
Alprostadil—Diarrhoea—Methotrexate—esophageal cancer	0.000111	0.0016	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—CXCL2—esophageal cancer	0.00011	0.000863	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL2—esophageal cancer	0.00011	0.000863	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—SST—esophageal cancer	0.00011	0.000859	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—SST—esophageal cancer	0.00011	0.000859	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GNG7—esophageal cancer	0.000109	0.000856	CbGpPWpGaD
Alprostadil—Dizziness—Methotrexate—esophageal cancer	0.000108	0.00154	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—GHRL—esophageal cancer	0.000107	0.000837	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GHRL—esophageal cancer	0.000107	0.000837	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ELMO1—esophageal cancer	0.000107	0.000835	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HSPA5—esophageal cancer	0.000106	0.000829	CbGpPWpGaD
Alprostadil—ABCC5—Disease—GSTO1—esophageal cancer	0.000104	0.000816	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TPI1—esophageal cancer	0.000104	0.000816	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000103	0.00081	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CSNK1A1—esophageal cancer	0.000103	0.00081	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000103	0.00081	CbGpPWpGaD
Alprostadil—Rash—Methotrexate—esophageal cancer	0.000103	0.00147	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—esophageal cancer	0.000103	0.00147	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—XIAP—esophageal cancer	0.000102	0.000802	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ANXA1—esophageal cancer	0.000102	0.000802	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ANXA1—esophageal cancer	0.000102	0.000802	CbGpPWpGaD
Alprostadil—Headache—Methotrexate—esophageal cancer	0.000102	0.00146	CcSEcCtD
Alprostadil—ABCC5—Metabolism—ADH1B—esophageal cancer	0.000101	0.000791	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ALDOB—esophageal cancer	9.99e-05	0.000783	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—SST—esophageal cancer	9.96e-05	0.00078	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—SST—esophageal cancer	9.96e-05	0.00078	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	9.92e-05	0.000777	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—HMOX1—esophageal cancer	9.88e-05	0.000774	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	9.8e-05	0.000768	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GHRL—esophageal cancer	9.7e-05	0.00076	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GHRL—esophageal cancer	9.7e-05	0.00076	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CTNNA1—esophageal cancer	9.68e-05	0.000759	CbGpPWpGaD
Alprostadil—Nausea—Methotrexate—esophageal cancer	9.67e-05	0.00139	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—PFN1—esophageal cancer	9.67e-05	0.000757	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PFN1—esophageal cancer	9.67e-05	0.000757	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TYMP—esophageal cancer	9.65e-05	0.000756	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL2—esophageal cancer	9.63e-05	0.000754	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HIST1H2BM—esophageal cancer	9.62e-05	0.000753	CbGpPWpGaD
Alprostadil—ABCC5—Disease—GAPDH—esophageal cancer	9.62e-05	0.000753	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—PIK3CA—esophageal cancer	9.51e-05	0.000745	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ABCB1—esophageal cancer	9.48e-05	0.000743	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NOS2—esophageal cancer	9.48e-05	0.000743	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP26A1—esophageal cancer	9.39e-05	0.000735	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALOX15—esophageal cancer	9.15e-05	0.000717	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PSME2—esophageal cancer	8.99e-05	0.000705	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PSME1—esophageal cancer	8.99e-05	0.000705	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ANXA1—esophageal cancer	8.95e-05	0.000701	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTO1—esophageal cancer	8.73e-05	0.000684	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TPI1—esophageal cancer	8.73e-05	0.000684	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SST—esophageal cancer	8.71e-05	0.000682	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ELMO1—esophageal cancer	8.68e-05	0.00068	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ELMO1—esophageal cancer	8.68e-05	0.00068	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—MYC—esophageal cancer	8.51e-05	0.000667	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—CREBBP—esophageal cancer	8.51e-05	0.000667	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	8.5e-05	0.000666	CbGpPWpGaD
Alprostadil—ABCC5—Disease—XIAP—esophageal cancer	8.49e-05	0.000665	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKAP13—esophageal cancer	8.49e-05	0.000665	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOTCH3—esophageal cancer	8.49e-05	0.000665	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKAP13—esophageal cancer	8.49e-05	0.000665	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GHRL—esophageal cancer	8.49e-05	0.000665	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALDOB—esophageal cancer	8.37e-05	0.000655	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FBXW7—esophageal cancer	8.35e-05	0.000654	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GAPDH—esophageal cancer	8.05e-05	0.000631	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CRABP1—esophageal cancer	7.98e-05	0.000625	CbGpPWpGaD
Alprostadil—ABCC5—Disease—B2M—esophageal cancer	7.9e-05	0.000619	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ABL1—esophageal cancer	7.84e-05	0.000614	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HIST1H2BM—esophageal cancer	7.83e-05	0.000614	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HIST1H2BM—esophageal cancer	7.83e-05	0.000614	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDE4D—esophageal cancer	7.76e-05	0.000608	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDE4D—esophageal cancer	7.76e-05	0.000608	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NOS3—esophageal cancer	7.62e-05	0.000597	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOTCH2—esophageal cancer	7.61e-05	0.000596	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNG7—esophageal cancer	7.59e-05	0.000595	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ENO1—esophageal cancer	7.57e-05	0.000593	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PSME1—esophageal cancer	7.46e-05	0.000584	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PSME2—esophageal cancer	7.46e-05	0.000584	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNG7—esophageal cancer	7.38e-05	0.000578	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNG7—esophageal cancer	7.38e-05	0.000578	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CALR—esophageal cancer	7.16e-05	0.000561	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALDH2—esophageal cancer	7.11e-05	0.000557	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FBXW7—esophageal cancer	6.92e-05	0.000542	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—XIAP—esophageal cancer	6.92e-05	0.000542	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—XIAP—esophageal cancer	6.92e-05	0.000542	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—HMOX1—esophageal cancer	6.85e-05	0.000536	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTT1—esophageal cancer	6.77e-05	0.00053	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFBR2—esophageal cancer	6.75e-05	0.000529	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP2A6—esophageal cancer	6.69e-05	0.000524	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.63e-05	0.000519	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ABCB1—esophageal cancer	6.57e-05	0.000515	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CTNNA1—esophageal cancer	6.54e-05	0.000512	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CTNNA1—esophageal cancer	6.54e-05	0.000512	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL2—esophageal cancer	6.5e-05	0.00051	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL2—esophageal cancer	6.5e-05	0.00051	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SMAD4—esophageal cancer	6.39e-05	0.000501	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ENO1—esophageal cancer	6.34e-05	0.000497	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS1—esophageal cancer	6.34e-05	0.000497	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—CREBBP—esophageal cancer	6.34e-05	0.000496	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PSME2—esophageal cancer	6.25e-05	0.000489	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PSME1—esophageal cancer	6.25e-05	0.000489	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSME2—esophageal cancer	6.08e-05	0.000476	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSME1—esophageal cancer	6.08e-05	0.000476	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSME1—esophageal cancer	6.08e-05	0.000476	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSME2—esophageal cancer	6.08e-05	0.000476	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ANXA1—esophageal cancer	6.05e-05	0.000474	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ANXA1—esophageal cancer	6.05e-05	0.000474	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SST—esophageal cancer	5.88e-05	0.000461	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SST—esophageal cancer	5.88e-05	0.000461	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—EP300—esophageal cancer	5.8e-05	0.000454	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GHRL—esophageal cancer	5.73e-05	0.000449	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH3—esophageal cancer	5.73e-05	0.000449	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GHRL—esophageal cancer	5.73e-05	0.000449	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH3—esophageal cancer	5.73e-05	0.000449	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS2—esophageal cancer	5.65e-05	0.000443	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FBXW7—esophageal cancer	5.64e-05	0.000442	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FBXW7—esophageal cancer	5.64e-05	0.000442	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFBR2—esophageal cancer	5.6e-05	0.000439	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1B1—esophageal cancer	5.39e-05	0.000422	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SMAD4—esophageal cancer	5.3e-05	0.000415	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HIF1A—esophageal cancer	5.23e-05	0.00041	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH2—esophageal cancer	5.14e-05	0.000403	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH2—esophageal cancer	5.14e-05	0.000403	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CREBBP—esophageal cancer	5.07e-05	0.000397	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP19A1—esophageal cancer	5.07e-05	0.000397	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KDR—esophageal cancer	5e-05	0.000392	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	4.96e-05	0.000388	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOTCH1—esophageal cancer	4.71e-05	0.000369	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMOX1—esophageal cancer	4.63e-05	0.000362	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFBR2—esophageal cancer	4.56e-05	0.000357	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFBR2—esophageal cancer	4.56e-05	0.000357	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS3—esophageal cancer	4.54e-05	0.000356	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ABCB1—esophageal cancer	4.44e-05	0.000348	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.39e-05	0.000344	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HIF1A—esophageal cancer	4.34e-05	0.00034	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SMAD4—esophageal cancer	4.32e-05	0.000338	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SMAD4—esophageal cancer	4.32e-05	0.000338	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—esophageal cancer	4.29e-05	0.000336	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CREBBP—esophageal cancer	4.27e-05	0.000335	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—esophageal cancer	4.2e-05	0.000329	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—esophageal cancer	4.15e-05	0.000325	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—esophageal cancer	4.01e-05	0.000314	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS2—esophageal cancer	3.95e-05	0.000309	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOTCH1—esophageal cancer	3.91e-05	0.000306	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOS3—esophageal cancer	3.82e-05	0.0003	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—esophageal cancer	3.64e-05	0.000285	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB2—esophageal cancer	3.58e-05	0.00028	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CREBBP—esophageal cancer	3.54e-05	0.000278	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HIF1A—esophageal cancer	3.53e-05	0.000277	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HIF1A—esophageal cancer	3.53e-05	0.000277	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—EP300—esophageal cancer	3.46e-05	0.000271	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KDR—esophageal cancer	3.38e-05	0.000265	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KDR—esophageal cancer	3.38e-05	0.000265	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH1—esophageal cancer	3.18e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH1—esophageal cancer	3.18e-05	0.000249	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS3—esophageal cancer	3.17e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—esophageal cancer	3.16e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1A—esophageal cancer	3.06e-05	0.00024	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CREBBP—esophageal cancer	2.97e-05	0.000232	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB2—esophageal cancer	2.97e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EP300—esophageal cancer	2.91e-05	0.000228	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—esophageal cancer	2.9e-05	0.000227	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CREBBP—esophageal cancer	2.89e-05	0.000226	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CREBBP—esophageal cancer	2.89e-05	0.000226	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—esophageal cancer	2.84e-05	0.000222	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—esophageal cancer	2.84e-05	0.000222	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.71e-05	0.000212	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—esophageal cancer	2.71e-05	0.000212	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NOS3—esophageal cancer	2.66e-05	0.000208	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOS3—esophageal cancer	2.58e-05	0.000202	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOS3—esophageal cancer	2.58e-05	0.000202	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—esophageal cancer	2.56e-05	0.0002	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1A—esophageal cancer	2.54e-05	0.000199	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—esophageal cancer	2.54e-05	0.000199	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—esophageal cancer	2.48e-05	0.000194	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—esophageal cancer	2.47e-05	0.000194	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—esophageal cancer	2.46e-05	0.000193	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—esophageal cancer	2.46e-05	0.000193	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—esophageal cancer	2.43e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB2—esophageal cancer	2.42e-05	0.000189	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB2—esophageal cancer	2.42e-05	0.000189	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EP300—esophageal cancer	2.41e-05	0.000189	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—esophageal cancer	2.15e-05	0.000169	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—esophageal cancer	2.13e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—esophageal cancer	2.13e-05	0.000167	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—esophageal cancer	2.1e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—esophageal cancer	2.08e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1A—esophageal cancer	2.07e-05	0.000162	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1A—esophageal cancer	2.07e-05	0.000162	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—esophageal cancer	2.06e-05	0.000161	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—EP300—esophageal cancer	2.02e-05	0.000158	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EP300—esophageal cancer	1.97e-05	0.000154	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EP300—esophageal cancer	1.97e-05	0.000154	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—esophageal cancer	1.79e-05	0.00014	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—esophageal cancer	1.71e-05	0.000134	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—esophageal cancer	1.71e-05	0.000134	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—esophageal cancer	1.67e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—esophageal cancer	1.67e-05	0.000131	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—esophageal cancer	1.49e-05	0.000117	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—esophageal cancer	1.45e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—esophageal cancer	1.45e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—esophageal cancer	1.41e-05	0.00011	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—esophageal cancer	1.41e-05	0.00011	CbGpPWpGaD
